Compare Cronos Group Inc (CRON) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs JPMorgan Chase & Co — how do they compare? Cronos Group Inc trades at $3.02 (market cap $1.11B), while JPMorgan Chase & Co trades at $361.62 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 861.6× Cronos Group Inc's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | JPM | |
|---|---|---|
Market Cap | $1.11B | $956.39B |
Sector | Health | Financials |
52-Week High | $3.27 | $359.79 |
52-Week Low | $2.30 | $282.84 |
Enterprise Value | $310.67M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
JPMorgan Chase & Co. (JPM) trades at $361.15, up 1.02% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.9B projected for 2026. The stock shows strong profitability with a net income margin of 33.38% and ROE of 18.43%, though cash flow trends indicate operational outflows.
Outlook remains positive due to earnings momentum and institutional support, but risks include geopolitical tensions affecting oil prices and cybersecurity threats highlighted in recent news. The stock's valuation at a P/E of 15.42 offers room for growth, but investors should monitor debt levels and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
